SciELO - Scientific Electronic Library Online

 
vol.9 issue2Concordance of dengue antigens M antibody-capture ELISA (MAC ELISA) in the IICS-UNACommunity epidemiological surveillance system "Bonis". Current status and future projections author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

  • Have no cited articlesCited by SciELO

Related links

  • Have no similar articlesSimilars in SciELO

Share


Memorias del Instituto de Investigaciones en Ciencias de la Salud

On-line version ISSN 1812-9528

Abstract

CAMPOS, S; FIGUEREDO THIEL, S  and  KASAMATSU, E. Expression of p53 protein in Barret’s esophagus and esophageal cancer. Experience of the Department of Pathology, IICS. Mem. Inst. Investig. Cienc. Salud [online]. 2011, vol.9, n.2, pp.50-56. ISSN 1812-9528.

ABSTRACT Barrett's esophagus is the change of the squamous epithelium to columnar (metaplasia) secondary to gastro-oesophageal reflux.The clinical significance is a predisposition to ulcers, bleeding and development of adenocarcinoma.It is not known the time needed for the development of dysplasia and the transition to carcinoma, which makes necessary to have indicators of neoplastic progression or malignant transformation. p53 protein participates in cell cycle control, DNA synthesis and repair and programmed cell death. Numerous papers describe the accumulation of p53 protein in esophageal dysplastic lesions, suggesting that this alteration would participate in esophageal tumorigenesis. The objective of this work was to determine the expression of p53 by immunohistochemistry in 58 esophageal biopsies of which 42 corresponded to Barret’s esophagus and esophageal and 16 to esophageal adenocarcinoma, describing the frequency of expression of p53, as well as the clinical, endoscopic and histological characteristics of the lesions. p53 expression was positive in 15/42 (36%) cases of Barrett's esophagus; the frequency was higher in those with esophagitis and in patients with dysplasia than in those without these characteristics. On the other hand, p53 was positive in 9/16 (56%) of adenocarcinomas. The study of p53 in these two entities could be used as an indicator that contributes to a better management of the disease in these patients.

Keywords : p53; Barrett's esophagus; adenocarcinoma; immunohistochemistry.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License